JAMA latest: Over 50% of Chinese adults have diabetes or are in the pre-disease stage

Non-communicable diseases, such as diabetes, tumors, and cardiovascular diseases are the most important causes of death in the global population, and their prevention and control are also important public health challenges facing the world

According to statistics, the prevalence of diabetes in China has risen from less than 1% during 1980 to around 11% in 2013, and it has become the country with the largest number of diabetes patients in the world

So since 2013, how has the prevalence and treatment of diabetes in China changed? On December 28, 2021, the Journal of the American Medical Association (JAMA) published the latest statistics on diabetes prevalence and treatment in China from 2013 to 2018

According to the results of this survey, the prevalence of adult diabetes in China rose from 10.

The paper pointed out that the current study is based on a large number of samples (170,287 and 173,642 subjects were included in the final analysis in 2013 and 2018), and it provides the latest statistics on the prevalence, treatment level, and risk factors of diabetes in China

The China Chronic Disease and Risk Factors Surveillance (China Chronic Disease and Risk Factors Surveillance) study is an ongoing, periodic, and nationally representative cross-sectional survey

The data of the current investigation and research on diabetes prevalence and treatment in China are derived from the above-mentioned research

research shows:

According to the survey data of 173642 subjects (median age 51.

In 2018, the awareness rate of diabetes was 36.

There are differences in the prevalence and treatment of diabetes in different genders, ages and places of residence

The paper pointed out that the overall prevalence and treatment results of diabetes in China derived from the current research may be affected by many factors, such as behavioral factors (including smoking, dietary intake, sedentary life>

In the past 20 years, the obesity rate of the Chinese population has increased rapidly.

Specifically, between 2013 and 2018, the proportion of current smokers dropped from 27.

Due to the large number of pre-diabetic populations, combined with the general changes in people's life>

"China Type 2 Diabetes Prevention Guidelines (2020 Edition)" proposes that for more than half of patients with type 2 diabetes who have no obvious early clinical manifestations, diabetes screening (mainly a two-point method, namely fasting blood glucose + 75 g oral glucose tolerance test 2 h Blood sugar) can make it "early detection and early treatment"

In addition, diabetes should adopt a comprehensive treatment strategy: while carrying out comprehensive interventions on blood sugar, blood pressure, blood lipids, body weight, etc.

summary

According to the latest research estimates, the incidence of diabetes in adults in China is not only still high (reaching 12.
4%; the global prevalence of diabetes in 2019 was 8.
3%), but also showing an increasing trend
.
At the same time, diabetes awareness, treatment and control rates have been kept at a low level
.
As the overweight/obesity rate of the Chinese population is also not optimistic, based on the general impact of the overall population’s life>
.

The findings of this study have important clinical and public health implications
.
In view of the current "three lows" of diabetes patients in China, that is, the low awareness rate, low treatment rate, and low control rate, it is necessary for us to take comprehensive actions in the future to address the burden of diabetes from multiple perspectives such as health, economy, and society, and formulate More comprehensive, personalized and sustainable interventions
.

Reference

[1] Wang L, Peng W, Zhao Z, et al.
Prevalence and Treatment of Diabetes in China, 2013-2018.
JAMA.
2021;326(24):2498–2506.
doi:10.
1001/jama.
2021.
22208

[2] Diabetes Branch of Chinese Medical Association.
Guidelines for Prevention and Treatment of Type 2 Diabetes in China (2020 Edition) [J].
Chinese Journal of Diabetes, 2021, 13(4): 317-411.
DOI:10.
3760/cma.
j.
cn115791-20210221 -00095.

(The original text has been deleted)